Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
0.0%
operating margin TTM
0.0%
revenue TTM
2.32 Million
revenue per share TTM
0.02$
valuation ratios | |
|---|---|
| pe ratio | -9.43 |
| peg ratio | -0.38 |
| price to book ratio | 54.11 |
| price to sales ratio | 0.00 |
| enterprise value multiple | -1.64 |
| price fair value | 54.11 |
profitability ratios | |
|---|---|
| gross profit margin | 0.0% |
| operating profit margin | 0.0% |
| pretax profit margin | 0.0% |
| net profit margin | 0.0% |
| return on assets | -134.69% |
| return on equity | -404.63% |
| return on capital employed | -425.5% |
liquidity ratio | |
|---|---|
| current ratio | 1.28 |
| quick ratio | 1.28 |
| cash ratio | 1.08 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 1,241.51 |
| cash conversion cycle | -1,241.51 |
| receivables turnover | 0.00 |
| payables turnover | 0.29 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.10 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.09 |
| interest coverage | -452.35 |
| cash flow to debt ratio | -36.97 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.04 |
| cash per share | 0.04 |
| operating cash flow per share | -0.04 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -36.97 |
| short term coverage ratios | -310.60 |
| capital expenditure coverage ratio | -396.88 |
Frequently Asked Questions
When was the last time Unicycive Therapeutics, Inc. (NASDAQ:UNCY) reported earnings?
Unicycive Therapeutics, Inc. (UNCY) published its most recent earnings results on 13-11-2024.
What is Unicycive Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Unicycive Therapeutics, Inc. (NASDAQ:UNCY)'s trailing twelve months ROE is -404.63%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Unicycive Therapeutics, Inc. (UNCY) currently has a ROA of -134.69%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did UNCY's net profit margin stand at?
UNCY reported a profit margin of 0.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is UNCY's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.28 in the most recent quarter. The quick ratio stood at 1.28, with a Debt/Eq ratio of 0.10.